Refractory Ovarian Carcinoma Recruiting Phase 2 Trials for Dordaviprone (DB14844)

IndicationStatusPhase
DBCOND0110942 (Refractory Ovarian Carcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04055649ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian CancerTreatment